244 related articles for article (PubMed ID: 36372767)
21. Clinical Utility of Universal Germline Genetic Testing for Patients With Breast Cancer.
Whitworth PW; Beitsch PD; Patel R; Rosen B; Compagnoni G; Baron PL; Simmons R; Brown EA; Gold L; Holmes D; Smith LA; Kinney M; Grady I; Clark P; Barbosa K; Lyons S; Riley L; Coomer C; Curcio L; Ruiz A; Khan S; MacDonald H; Hughes K; Hardwick MK; Heald B; Munro SB; Nielsen SM; Esplin ED
JAMA Netw Open; 2022 Sep; 5(9):e2232787. PubMed ID: 36136330
[TBL] [Abstract][Full Text] [Related]
22. Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA.
Schrader KA; Cheng DT; Joseph V; Prasad M; Walsh M; Zehir A; Ni A; Thomas T; Benayed R; Ashraf A; Lincoln A; Arcila M; Stadler Z; Solit D; Hyman DM; Zhang L; Klimstra D; Ladanyi M; Offit K; Berger M; Robson M
JAMA Oncol; 2016 Jan; 2(1):104-11. PubMed ID: 26556299
[TBL] [Abstract][Full Text] [Related]
23. Dissecting the Role of BET Bromodomain Proteins BRD2 and BRD4 in Human NK Cell Function.
Cribbs AP; Filippakopoulos P; Philpott M; Wells G; Penn H; Oerum H; Valge-Archer V; Feldmann M; Oppermann U
Front Immunol; 2021; 12():626255. PubMed ID: 33717143
[TBL] [Abstract][Full Text] [Related]
24. Frequency of actionable germline pathogenic variants identified through tumor next-generation sequencing in a gynecologic cancer cohort.
Karpel H; Manderski E; Pothuri B
Int J Gynecol Cancer; 2023 Jul; 33(7):1044-1050. PubMed ID: 36889816
[TBL] [Abstract][Full Text] [Related]
25. Germline breast cancer susceptibility gene mutations and breast cancer outcomes.
Wang YA; Jian JW; Hung CF; Peng HP; Yang CF; Cheng HS; Yang AS
BMC Cancer; 2018 Mar; 18(1):315. PubMed ID: 29566657
[TBL] [Abstract][Full Text] [Related]
26. Identification of pathogenic germline variants in a large Chinese lung cancer cohort by clinical sequencing.
Yu Z; Zhang Z; Liu J; Wu X; Fan X; Pang J; Bao H; Yin J; Wu X; Shao Y; Liu Z; Liu F
Mol Oncol; 2024 May; 18(5):1301-1315. PubMed ID: 37885353
[TBL] [Abstract][Full Text] [Related]
27. Detection of Pathogenic Variants With Germline Genetic Testing Using Deep Learning vs Standard Methods in Patients With Prostate Cancer and Melanoma.
AlDubayan SH; Conway JR; Camp SY; Witkowski L; Kofman E; Reardon B; Han S; Moore N; Elmarakeby H; Salari K; Choudhry H; Al-Rubaish AM; Al-Sulaiman AA; Al-Ali AK; Taylor-Weiner A; Van Allen EM
JAMA; 2020 Nov; 324(19):1957-1969. PubMed ID: 33201204
[TBL] [Abstract][Full Text] [Related]
28. Rare Variants in Known Susceptibility Loci and Their Contribution to Risk of Lung Cancer.
Liu Y; Lusk CM; Cho MH; Silverman EK; Qiao D; Zhang R; Scheurer ME; Kheradmand F; Wheeler DA; Tsavachidis S; Armstrong G; Zhu D; Wistuba II; Chow CB; Behrens C; Pikielny CW; Neslund-Dudas C; Pinney SM; Anderson M; Kupert E; Bailey-Wilson J; Gaba C; Mandal D; You M; de Andrade M; Yang P; Field JK; Liloglou T; Davies M; Lissowska J; Swiatkowska B; Zaridze D; Mukeriya A; Janout V; Holcatova I; Mates D; Milosavljevic S; Scelo G; Brennan P; McKay J; Liu G; Hung RJ; Christiani DC; Schwartz AG; Amos CI; Spitz MR
J Thorac Oncol; 2018 Oct; 13(10):1483-1495. PubMed ID: 29981437
[TBL] [Abstract][Full Text] [Related]
29. Role of MYH polymorphisms in sporadic colorectal cancer in China: a case-control, population-based study.
Yang L; Huang XE; Xu L; Zhou JN; Yu DS; Zhou X; Li DZ; Guan X
Asian Pac J Cancer Prev; 2013; 14(11):6403-9. PubMed ID: 24377541
[TBL] [Abstract][Full Text] [Related]
30. Whole genome sequencing identifies rare germline variants enriched in cancer related genes in first degree relatives of familial pancreatic cancer patients.
Tan M; Brusgaard K; Gerdes AM; Mortensen MB; Detlefsen S; Schaffalitzky de Muckadell OB; Joergensen MT
Clin Genet; 2021 Nov; 100(5):551-562. PubMed ID: 34313325
[TBL] [Abstract][Full Text] [Related]
31. NBN Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and In Vitro DNA Damage Response Defects.
Belhadj S; Khurram A; Bandlamudi C; Palou-Márquez G; Ravichandran V; Steinsnyder Z; Wildman T; Catchings A; Kemel Y; Mukherjee S; Fesko B; Arora K; Mehine M; Dandiker S; Izhar A; Petrini J; Domchek S; Nathanson KL; Brower J; Couch F; Stadler Z; Robson M; Walsh M; Vijai J; Berger M; Supek F; Karam R; Topka S; Offit K
Clin Cancer Res; 2023 Jan; 29(2):422-431. PubMed ID: 36346689
[TBL] [Abstract][Full Text] [Related]
32. Bromodomain and Extra-Terminal (BET) Domain Protein Inhibitors for Solid Tumor Cancers.
Nguyen MV; Loof L; Falchook GS
J Immunother Precis Oncol; 2020 Feb; 3(1):16-22. PubMed ID: 35756176
[TBL] [Abstract][Full Text] [Related]
33. The conserved 12-amino acid stretch in the inter-bromodomain region of BET family proteins functions as a nuclear localization signal.
Fukazawa H; Masumi A
Biol Pharm Bull; 2012; 35(11):2064-8. PubMed ID: 22971749
[TBL] [Abstract][Full Text] [Related]
34. Bromodomain and extra-terminal domain bromodomain inhibition prevents synovial inflammation via blocking IκB kinase-dependent NF-κB activation in rheumatoid fibroblast-like synoviocytes.
Xiao Y; Liang L; Huang M; Qiu Q; Zeng S; Shi M; Zou Y; Ye Y; Yang X; Xu H
Rheumatology (Oxford); 2016 Jan; 55(1):173-84. PubMed ID: 26324948
[TBL] [Abstract][Full Text] [Related]
35. Rare, Pathogenic Germline Variants in
Esai Selvan M; Klein RJ; Gümüş ZH
Clin Cancer Res; 2019 Mar; 25(5):1517-1525. PubMed ID: 30425093
[TBL] [Abstract][Full Text] [Related]
36. Bromodomain and extraterminal proteins suppress NF-E2-related factor 2-mediated antioxidant gene expression.
Michaeloudes C; Mercado N; Clarke C; Bhavsar PK; Adcock IM; Barnes PJ; Chung KF
J Immunol; 2014 May; 192(10):4913-4920. PubMed ID: 24733848
[TBL] [Abstract][Full Text] [Related]
37.
Petrova M; Margasyuk S; Vorobeva M; Skvortsov D; Dontsova OA; Pervouchine DD
NAR Genom Bioinform; 2024 Mar; 6(1):lqad113. PubMed ID: 38226395
[TBL] [Abstract][Full Text] [Related]
38. Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 (CHEK2) With Susceptibility to Testicular Germ Cell Tumors.
AlDubayan SH; Pyle LC; Gamulin M; Kulis T; Moore ND; Taylor-Weiner A; Hamid AA; Reardon B; Wubbenhorst B; Godse R; Vaughn DJ; Jacobs LA; Meien S; Grgic M; Kastelan Z; Markt SC; Damrauer SM; Rader DJ; Kember RL; Loud JT; Kanetsky PA; Greene MH; Sweeney CJ; Kubisch C; Nathanson KL; Van Allen EM; Stewart DR; Lessel D;
JAMA Oncol; 2019 Apr; 5(4):514-522. PubMed ID: 30676620
[TBL] [Abstract][Full Text] [Related]
39. Yield and Utility of Germline Testing Following Tumor Sequencing in Patients With Cancer.
Lincoln SE; Nussbaum RL; Kurian AW; Nielsen SM; Das K; Michalski S; Yang S; Ngo N; Blanco A; Esplin ED
JAMA Netw Open; 2020 Oct; 3(10):e2019452. PubMed ID: 33026450
[TBL] [Abstract][Full Text] [Related]
40. Germline pathogenic variant spectrum in 25 cancer susceptibility genes in Turkish breast and colorectal cancer patients and elderly controls.
Akcay IM; Celik E; Agaoglu NB; Alkurt G; Kizilboga Akgun T; Yildiz J; Enc F; Kir G; Canbek S; Kilic A; Zemheri E; Ezberci F; Ozcelik M; Dinler Doganay G; Doganay L
Int J Cancer; 2021 Jan; 148(2):285-295. PubMed ID: 32658311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
